TP53 and mantle cell lymphoma: We next performed a meta-analysis on the public datasets from multiple MCL studies containing a total of 2008 evaluable MCL samples at either baseline or disease progression [39] and found the frequencies of concurrent mutations in ATM and TP53 at disease progression are apparently higher than that at baseline (Fig. 1b).